Dr Danijela Tatovic
Timau a rolau for Danijela Tatovic
Uwch Gymrawd Ymchwil Anrhydeddus
Cyhoeddiad
2026
- Taylor, P. N. et al. 2026. Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes. Diabetologia (10.1007/s00125-026-06798-z)
- Dunseath, G. J. et al., 2026. Serial dried blood spot c-peptide sampling, but not urine c-peptide-to-creatinine ratio, detects early preservation of β-cell function in new-onset type 1 diabetes: experience from the USTEKID trial. Diabetes Care 49 (7), pp.1-8. (10.2337/dc25-2896)
- Tatovic, D. and Dayan, C. 2026. Clinical immunologic interventions for the treatment of type 1 diabetes: challenges, choice, and timing of immunomodulators. Cold Spring Harbor Perspectives in Medicine 16 (4) a041597. (10.1101/cshperspect.a041597)
2025
- Thomas, N. et al., 2025. Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework. The Lancet Diabetes & Endocrinology 13 (11), pp.980-986. (10.1016/S2213-8587(25)00260-8)
- Carter, K. et al., 2025. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Efficacy and Mechanism Evaluation 12 (1), pp.1-66. (10.3310/fqln7416)
2024
- Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30 , pp.2657-2666. (10.1038/s41591-024-03115-2)
2023
- Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14 1276255. (10.3389/fimmu.2023.1276255)
- Tatovic, D. , Narendran, P. and Dayan, C. M. 2023. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nature Reviews Endocrinology 19 , pp.361-370. (10.1038/s41574-023-00816-5)
2022
- Tatovic, D. et al. 2022. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine 39 (7) e14862. (10.1111/dme.14862)
- Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)
2021
- Gregory, J. W. et al. 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11 (10) e049595. (10.1136/bmjopen-2021-049595)
- Hanna, S. J. et al. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12 751701. (10.3389/fimmu.2021.751701)
- Tatovic, D. and Dayan, C. M. 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38 e14696. (10.1111/dme.14696)
2019
- Yang, J. H. M. et al., 2019. Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry. Frontiers in Immunology 10 , pp.-. 2547. (10.3389/fimmu.2019.02547)
- Dayan, C. M. et al. 2019. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394 (10205), pp.1286-1296. (10.1016/S0140-6736(19)32127-0)
- Dul, M. et al. 2019. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics 562 , pp.303-312. (10.1016/j.ijpharm.2019.03.041)
2016
- Tatovic, D. et al. 2016. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33 (11), pp.1564-1568. (10.1111/dme.13186)
- Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223 , pp.178-187. (10.1016/j.jconrel.2015.12.040)
2015
- Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146 (3), pp.411-422. (10.1111/imm.12518)
- Tatovic, D. et al. 2015. Fine-needle aspiration biopsy of the lymph node: a novel tool for the monitoring of immune responses after skin antigen delivery. Journal of Immunology 195 (1), pp.386-392. (10.4049/jimmunol.1500364)
- Tatovic, D. 2015. Optimising the delivery and monitoring of peptide immunotherapythe delivery and monitoring of peptide immunotherapy for Type 1 diabetes. PhD Thesis , Cardiff University.
2013
Articles
- Taylor, P. N. et al. 2026. Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes. Diabetologia (10.1007/s00125-026-06798-z)
- Dunseath, G. J. et al., 2026. Serial dried blood spot c-peptide sampling, but not urine c-peptide-to-creatinine ratio, detects early preservation of β-cell function in new-onset type 1 diabetes: experience from the USTEKID trial. Diabetes Care 49 (7), pp.1-8. (10.2337/dc25-2896)
- Tatovic, D. and Dayan, C. 2026. Clinical immunologic interventions for the treatment of type 1 diabetes: challenges, choice, and timing of immunomodulators. Cold Spring Harbor Perspectives in Medicine 16 (4) a041597. (10.1101/cshperspect.a041597)
- Thomas, N. et al., 2025. Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework. The Lancet Diabetes & Endocrinology 13 (11), pp.980-986. (10.1016/S2213-8587(25)00260-8)
- Carter, K. et al., 2025. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Efficacy and Mechanism Evaluation 12 (1), pp.1-66. (10.3310/fqln7416)
- Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30 , pp.2657-2666. (10.1038/s41591-024-03115-2)
- Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14 1276255. (10.3389/fimmu.2023.1276255)
- Tatovic, D. , Narendran, P. and Dayan, C. M. 2023. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nature Reviews Endocrinology 19 , pp.361-370. (10.1038/s41574-023-00816-5)
- Tatovic, D. et al. 2022. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine 39 (7) e14862. (10.1111/dme.14862)
- Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)
- Gregory, J. W. et al. 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11 (10) e049595. (10.1136/bmjopen-2021-049595)
- Hanna, S. J. et al. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12 751701. (10.3389/fimmu.2021.751701)
- Tatovic, D. and Dayan, C. M. 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38 e14696. (10.1111/dme.14696)
- Yang, J. H. M. et al., 2019. Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry. Frontiers in Immunology 10 , pp.-. 2547. (10.3389/fimmu.2019.02547)
- Dayan, C. M. et al. 2019. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394 (10205), pp.1286-1296. (10.1016/S0140-6736(19)32127-0)
- Dul, M. et al. 2019. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics 562 , pp.303-312. (10.1016/j.ijpharm.2019.03.041)
- Tatovic, D. et al. 2016. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33 (11), pp.1564-1568. (10.1111/dme.13186)
- Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223 , pp.178-187. (10.1016/j.jconrel.2015.12.040)
- Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146 (3), pp.411-422. (10.1111/imm.12518)
- Tatovic, D. et al. 2015. Fine-needle aspiration biopsy of the lymph node: a novel tool for the monitoring of immune responses after skin antigen delivery. Journal of Immunology 195 (1), pp.386-392. (10.4049/jimmunol.1500364)
- Tatovic, D. et al. 2013. Topical steroid has the potential of modulating skin dendritic cells to tolerogenic antigen presenting cells in human organ skin bath culture [Abstract]. Diabetic Medicine 30 (s1), pp.53-53. (10.1111/dme.12091_1)
Thesis
- Tatovic, D. 2015. Optimising the delivery and monitoring of peptide immunotherapythe delivery and monitoring of peptide immunotherapy for Type 1 diabetes. PhD Thesis , Cardiff University.
